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Yes-associated protein (YAP) regulates DNA damage and chemosensitivity, as well as functioning as a pro-growth, cell
size regulator. For both of its roles, regulation by phosphorylation is crucial. We undertook an in vitro screen to identify novel
YAP kinases to discover new signaling pathways to better understand YAP’s function. We identiﬁed JNK1 and JNK2 as robust
YAP kinases, as well as mapped multiple sites of phosphorylation. Using inhibitors and siRNA, we showed that JNK speciﬁcally
phosphorylates endogenous YAP in a number of cell types. We show that YAP protects keratinocytes from UV irradiation but
promotesUV-inducedapoptosisinasquamouscellcarcinoma.WedeﬁnedthemechanismforthisdualroletobeYAP’sabilityto
bind and stabilize the pro-proliferative DNp63a isoform in a JNK-dependent manner. Our report indicates that an evaluation of
the expression of the different isoforms of p63 and p73 is crucial in determining YAP’s function.
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Yes-associated protein (YAP) was originally found as a
phosphoprotein that bound to the SH3 domain of the Src-family
kinase Yes, but was soon shown to deﬁne a novel protein-binding
module, the WW domain.
1,2 Subsequent work has determined
that YAP functions as a transcription modulator, binding to a
number of transcription factors, including RUNX2, p73, members
of the TEAD family and the C-terminal fragment of Erb-B4.
3–6
A number of functional studies of mammalian cells have
implicated YAP as a proapoptotic regulator. Upon DNA damage,
YAP binds to p73 downstream and promotes the selective
transcription by p73 of a number of proapoptotic genes such as
BAX and PIG3.
7–9 YAP and p73 form a complex with regulatory
proteins, including the p300 acetyltransferase and the pro-
myelocytic leukemia (PML) tumor-suppressor protein.
8,10,11
Whereas phosphorylation of YAP by the pro-survival Akt serine/
threonine kinase inhibits the binding of YAP and p73, this binding
is enhanced by phosphorylation of YAP by the DNA-damage
c-Abl tyrosine kinase.
7,9 Furthermore, YAP also stabilizes p73 by
displacing the ITCH E3 ubiquitin ligase by competitive binding,
further activating cell death.
12,13
Conversely, YAP has also been identiﬁed recently as a pro-
growth, cell size regulator in both Drosophila melanogaster and
mammalian cells.
14,15 In contrast to regulating apoptosis by
activation of p73, the growth control role of YAP or its ﬂy homolog,
Yorkie (Yki), is due to inactivation by the MST2 (HIPPO in ﬂy)
pathway.
16,17 Here, the tumor-suppressor LATS1 kinase (WTS in
ﬂy) directly phosphorylates YAP (Yki), inhibiting its co-activation
o ft h eT E A D( S c a l l o p e di nﬂ y )t r a n s c r i p t i o nf a c t o rt ou p r e g u l a t e
pro-growth genes.
18,19 However, phosphorylation of YAP by
MST2/LATS1 has also been shown to enhance p73 binding and
subsequent apoptosis downstream from Fas in human breast
cancer cells and chemotherapy in leukemia cells, as well as
overexpression of pathway members in HEK293 cells.
20–22
Clearly, phosphorylation is a key regulatory mechanism for
YAP.TofurtherunderstandtheroleofYAP,wesoughttodiscover
new signaling pathways that regulate YAP’s function. We wished
to identify kinases that directly phosphorylate YAP and then
functionallycharacterizethephosphorylationincellsinthecontext
of apoptosis. To this end, we performed an in vitro screen using
recombinant YAP anda panel of recombinant, activekinases.We
selected the kinasesonthe basisof their putativephosphorylation
site motifs expressed in YAP. Here we report the identiﬁcation of
JNK1 and JNK2 as kinases that robustly phosphorylate YAP and
regulate its function in apoptosis.
Results
Identiﬁcation of JNK as a YAP kinase. To ﬁnd novel YAP
kinases, a panel of 29 recombinant, candidate kinases was
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YAP phosphorylation was visualized by autoradiography of the
SDS-PAGE fractionation of
32P-labeled in vitro kinase reactions
and quantiﬁed (Figure 1 and Supplementary Table 1). Speciﬁc
activities of candidate kinases were validated by using
phosphorylation of control peptides (Supplementary Table S1).
We identiﬁed JNK1 (variant JNK1a1) and JNK2 (variant JNK2a2)
as strong YAP kinases (Figure 1 and Supplementary Table 1). In
addition, ERK2 and PKCa were also identiﬁed as moderate, and
CaMKII, PKCg and PKCy as weak, YAP kinases (Figure 1 and
Supplementary Table 1). On the basis of these initial ﬁndings
and the well-characterized role of JNKs in regulating apoptosis
and diseases such as cancer,
23–25 we focused our efforts to
pursue JNKs as putative YAP kinases. We performed time
courses of phosphorylation to determine whether both JNK1 and
JNK2 phosphorylated YAP stoichiometrically in vitro (Figure 2a).
A stepwise, time-dependent increase in YAP phosphorylation, as
determined by
32P incorporation (Figure 2a, bottom panels for
each kinase), was reﬂected through detectable molecular-weight
(MW) shifts on Coomassie-stained gels (Figure 2a, top panels).
These results suggest that both JNK1 and JNK2 phosphorylated
YAP on multiple sites.
JNK phosphorylates YAP on multiple sites. To identify
these sites, mass spectrometry (LC-MS/MS) was used to
analyze recombinant YAP that had been incubated with
either JNK1 or JNK2 for 60min for full phosphorylation, as
evidenced by pronounced MW shift (Figure 2b). In total, ﬁve
novel phosphorylation sites on YAP were identiﬁed: T119,
S138, T154, S317 and T362 (Figure 2b). Each of the serines
and threonines are followed by a proline and therefore
represent canonical JNK phosphorylation sites.
To ascertain if JNK phosphorylates YAP on the same sites in
vivo, we expressed a Flag-tagged YAP1 construct in 293 cells,
followed by treatment with the potent JNK signaling activator,
anisomycin.
26Immunoprecipitation (IP) of YAP from these cells
showed a clear anisomycin-induced MW band shift in YAP,
similar to that observed in vitro, by both Western blot analysis
and Coomassie staining (Figure 2c). LC-MS/MS analysis of the
in vivo JNK-stimulated YAP identiﬁed three phosphorylation
sites, S138, S317and T362,all ofwhichwerealsofoundfrom in
vitro analysis (Figure 2c). We mutated these residues individu-
ally to alanine to generate phospho-deﬁcient constructs, along
with the other two sites identiﬁed in vitro, T119 and T154. The
wild-type and ﬁve mutated Flag–YAP constructs were
expressedinU2OScells,followedbytreatmentwithanisomycin
to determine what effect these mutations would have on the
JNK-signature YAP band shift. The mutated constructs showed
varying degrees of band shift upon anisomycin treatment, with
theS317AandT362Amutantsshowingminimalshift,indicating
that these two sites are most responsible for in vivo
phosphorylation induced MW shift (Figure 2d).
JNK speciﬁcally phosphorylates YAP in vivo. To
determine whether JNK phosphorylates endogenous YAP1,
we activated JNK by treating cells with anisomycin and
detected the YAP band shift in a number of cells, including
the HaCaT keratinocyte, U20S osteosarcoma, MCF-7 breast
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Figure 1 Identiﬁcation of JNK1 and JNK2 as YAP kinases. Recombinant YAP was used in an in vitro screen with 29 recombinant, active kinases. Kinase reactions were
performed in duplicate and processed as described in the Supplementary information. Autoradiography of
32P-labeled ATP incorporation indicates that JNK1 and JNK2 are
strong YAP kinases, whereas Erk2 and PKCa phosphorylate YAP moderately well
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Cell Death and Diseasecancer and 293 human embryonic kidney cell lines
(Figure 3a). We conﬁrmed anisomycin activation of JNK by
phosphorylation of its target, c-Jun,
27 (Figure 3a). This
showed that JNK phosphorylation of YAP is not cell line-
speciﬁc. To further conﬁrm that the anisomycin-induced YAP
band shift was due to JNK activation, U2OS cells were
treated with a JNK-speciﬁc chemical inhibitor, SP600125,
28
before anisomycin treatment. The inhibitor prevented JNK
activation, as observed by a reduction in the phosphorylation
of c-Jun, and prevented the YAP band shift induced by
anisomycin (compare lanes 2 and 3 in Figure 3b, upper
panel). Although our in vitro screen indicated that only JNK1
and JNK2, and not other stress-activated MAPKs, that is, the
different p38 isoforms, phosphorylate YAP (Figure 1 and
Supplementary Table S1), we wished to rule out the possibility
that the YAP band shift is due to anisomycin-induced p38 MAPK
activation. HaCaT cells were pretreated with the speciﬁc p38
inhibitor, SB203580,
29 before anisomycin treatment. Western
blot analysis showed an anisomycin-induced shift in YAP in both
untreated and treated cells, conﬁrming that p38MAPK does not
phosphorylate YAP (Figure 3b, lower panel). The same lysates
were immunoblotted for the phosphorylated form of the direct
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Figure 2 JNKphosphorylatesYAPon multiplesites. (a) In vitro kinaseassaywhere recombinant YAP was incubatedwith JNK1a1 or JNK2a2. Theassaywas stoppedat
different time points from 0 to 60min and the samples were fractionated by SDS-PAGE, visualized by Coomassie staining (top) and for phosphorylation by incorporation of
32P-labeledATP(bottom).Eachtimepointisshowninduplicate.(b)ThekinasesJNK1a1orJNK2a2wereincubatedwithrecombinantYAPfor0or60mininaninvitrokinase
assay. The samples were visualized by Coomassie staining. The band containing the YAP protein was excised for analysis by mass spectrometry and the sites identiﬁed are
listed to the right of the panels. (c) 293T cells were transfected with a Flag–YAP expression vector or a Flag-empty vector. Twenty-four hours later the cells were treated with
anisomycin or DMSO before harvesting. Flag immunoprecipitated proteins were visualized by Coomassie staining and the band containing the Flag–YAP protein after
anisomycin treatment was excised and analyzed by mass spectrometry for phosphorylation; the sites identiﬁed are listed to the right of panel. Flag IP elutes and inputs were
also immunoblotted by the indicated antibodies. (d) The wild-type YAP (WT) and ﬁve mutant (T119A, S138A, T154A, S317A and T362A) Flag–YAP constructs were each
transfectedintoU2OScellsand24hlaterweretreatedwithanisomycinorDMSObeforeharvesting.Lysateswerefractionatedby8%SDS-PAGE,analyzedforYAPbandshift
and further probed with indicated antibodies
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Cell Death and Diseasep38 target, MAPKAPK2,
30 to show that SB203580 was
effective in inhibiting p38’s activity (Figure 3b, lower panel).
Furthermore, although we had identiﬁed ERK2 as a moderate
YAP kinase (Figure 1 and Supplementary Table S1), as
expected, anisomycin did not activate ERK1 or ERK2 in
these cells, as shown by immunoblotting with a phospho-ERK
antibody (Supplementary Figure 1). Our in vivo results conﬁrm
that JNK but not p38MAPKs phosphorylates endogenous
YAP in cells.
We attempted to raise phospho-speciﬁc antibodies against
the S317 and T362, the two sites that were most responsible
for in vivo phosphorylation-dependent band shift of YAP
(Figure 2d), and were successful in generating a T362-
speciﬁc antibody (pT362). The pT362 antibody was effective
when used on immunoprecipitated YAP from anisomycin-
treated cells (Figure 3c), conﬁrming our mass spectrometry
results (Figure 2c). In these experiments, we monitored the
anisomycin activation of JNK using a phospho-JNK antibody
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Figure 3 JNK speciﬁcally phosphorylates YAP in vivo.( a) HaCaT, U2OS, MCF7 and 293T cell lines were treated with anisomycin or DMSO (control) for 60min before
harvesting. YAP band shift was analyzed as described before and lysates were analyzed by Western blotting with the indicated antibodies. (b) Upper panel: U2OS cells were
treated with SP600125 or an equivalent volume of DMSO for 3h, followed by treatment for 15min with anisomycin or DMSO. Lower panel: HaCaT cells were treated with
SB203580orDMSOfor3hpriorfollowedbya15mintreatmentwithanisomycinorDMSO,harvestedandlysateswereanalyzedusingtheindicatedantibodies.(c)U2OScells
were transfected with Flag–YAP and either siControl (siCTL) or siJNK1 and siJNK2 (siJNK). The cells were then treated with anisomycin for 1h and subsequently Flag–YAP
was immunoprecipitatedfromlysates.IP inputs andeluateswere analyzedby Westernblotting usingtheindicatedantibodies.(d)BWTcells weretransfectedwith Flag–YAP,
Flag–mut2AYAP and Flag–mut2DYAP. Thecells wereirradiated with 30J/m
2 UV-C andharvested 1h later for Western blot analysiswith the indicatedantibodies.(e) HaCaT
cells were irradiated with 50J/m
2 UV-C and harvested at 10, 20, 30min and 2h. Endogenous YAP was immunoprecipitated and IP inputs and eluates were analyzed by
Western blotting using the indicated antibodies
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Cell Death and Disease(Figure 3c). Using short interfering RNA (siRNA), which
effectively silenced both JNK 1 and JNK2, phosphorylation on
threonine-362 of YAP was blocked by silencing JNK in both
anisomycin-treated and untreated cells, (Figure 3c). Blocking
anisomycin-induced phosphorylation of YAP, as determined
usingthe pT362 antibody, is consistent with our ﬁndings using
the JNK-speciﬁc chemical inhibitor in Figure 3b, further
conﬁrming that YAP is speciﬁcally phosphorylated by JNK
in vivo.
UV radiation is one of the best characterized and
physiologically relevant activators of JNK signaling.
24,31 We
assessed whether the same residues that we determined to
be the critical sites of anisomycin-induced JNK phosphoryla-
tion (Figure 2d and Figure 3c) were also sites of UV-induced
phosphorylation of YAP. We expressed either a phospho-
deﬁcient YAP mutant, where S317 and T362 were mutated to
alanine (S317A, T362A¼mut2AYAP), or a phospho-mimetic
YAP mutant, where the both residues were mutated to
aspartate (S317D, T362D¼mut2DYAP), or wild-type YAP
in BWT squamous cell carcinoma cells. Western blot analysis
shows that the mut2AYAP resolves at lower MW than wild-
type YAP, indicative of a less phosphorylated state, whereas
mut2DYAP resolves at a markedly higher MW, indicative of a
hyper-phosphorylated state and mimicking the JNK phospho-
rylation-dependent band shift from previous experiments
(Figure 3d). Similar to anisomycin, UV-C treatment caused a
band shift of wild-type YAP (Figure 3d). Moreover, this shift
resolved at an MW similar to untreated mut2DYAP
(Figure 3d). Most tellingly, UV treatment did not result in a
detectable band shift in either mutant YAP construct, showing
that S317 and T362 are the main target sites for UV-induced
YAP phosphorylation. To verify that UV exposure results in
JNK-dependentphosphorylationof endogenousYAP,HaCaT
cells were treated with a time course of UV-C radiation and
YAP was immunoprecipitated and subsequently immuno-
blotted with the pT362 antibody. As shown in Figure 3e, UV
radiation results in robust phosphorylation of YAP, as early as
30min and sustained through to 2h, similar to increase in
c-Junphosphorylation.Together,theseresultsshowthatYAP
is speciﬁcally phosphorylated by JNK upon UV radiation.
YAP has been shown to signal apoptosis downstream from
chemotherapeuticagentssuchascisplatin,aswellasionizing
radiation and treatment with Fas ligand,
7–9 but the role of YAP
in UV-induced apoptosis has not yet been investigated. We
selectedHaCaTasamodelsystem,asUV-inducedapoptosis
is particularly physiologically relevant in keratinocytes and
has been shown to be dependent on JNK in these cells.
32
Furthermore, we have shown JNK phosphorylation of YAP
upon UV radiation in HaCaT cells (Figure 3e). To study the
effects of YAP expression in these cells, we generated
control and YAP shRNA stable cell lines and subjected
them to 50J/m
2 UV irradiation. At 24h after treatment,
40% apoptosis was observed in the control cells (as
measured by FACS analysis of Annexin-V and propidium
iodide (PI) staining, both early and late apoptosis). YAP
silencing resulted in considerably more death, with 70%
apoptosis evident in YAP shRNA cells (Figure 4a and
Supplementary Figure 2a). Noticeably, stable YAP loss alone
did not cause death in these cells (Figure 4a and Supple-
mentary Figure 2a). YAP silencing and JNK activation as
shown by phosphorylated c-Jun levels were maintained at
24hofUVtreatment(SupplementaryFigure2b).Westernblot
analysis of lysates from similarly treated cells showed that
YAP silencing enhanced UV-induced PARP cleavage, a
hallmark of apoptosis, at time points as early as 2h
(Figure 4b). Interestingly, anisomycin treatment, which
resulted in comparable levels of JNK activity, as shown by
phosphorylated c-Jun levels, also similarly enhanced PARP
cleavage in YAP shRNA stable cells (Figure 4b). These
results indicate that YAP expression protects from UV-
induced, JNK-mediated apoptosis in keratinocytes.
As described earlier, this ﬁnding is contrary to what has
been reported previously for YAP’s role in other DNA-
damaging stimuli in tumor-derived cells. We next examined
how YAP’s expression regulated UV-induced apoptosis in a
skin cancer cell line. BWT squamous cell carcinoma cells
treated with control siRNA subject to 30J/m
2 UV for 24h
resulted in over 40% total apoptosis as measured by FACS
analysis. YAP siRNA-treated cells irradiated similarly were
markedly protected from UV-induced cell death, showing only
18% apoptosis (Figure 4c). As shown in Figure 4d, efﬁcient
silencing of YAP in these cells also inhibited UV-induced
PARP cleavage at 6h. To investigate whether JNK phospho-
rylation of YAP regulates its proapoptotic role in this skin
cancer cell line, we expressed either an empty vector or the
mut2DYAP plasmid and irradiated with UV as before.
Tellingly, expression of the JNK-site phosphomimetic YAP
construct alone resulted in a level of apoptosis similar as that
observed with UV irradiation of the empty vector control cells
(Figure 4e). This corroborated with our results in Figure 3d
where we show that expression of mut2DYAP alone mimics
the UV-induced band shift of wild-type YAP in BWT. In
contrast to our results in HaCaT keratinocytes (Figure 4a and
b), these ﬁndings show that endogenous YAP expression
promotes UV-induced apoptosis in BWT, in a JNK phosphor-
ylation-dependent manner.
JNK phosphorylation of YAP enhances its stabilization
of DNp63a by direct binding. We have recently reported
that YAP promotes cisplatin-induced, c-Jun-mediated
apoptosis, in part by stabilizing the proapoptotic TAp73a
isoform, a mechanism also shown by others.
12,13 HaCaT
cells more abundantly express the DNp63a isoform, which
has been shown to be crucial for proliferation, differentiation
and actually protective from p73-dependent cell death.
33–36
However, the PPXY motif required for YAP binding present
on the longer isoforms of p73 is also conserved on DNp63a.
4
We examined whether YAP can also stabilize this protective
p53-family member in a JNK-dependent manner. In HaCaT
cells, silencing of endogenous YAP resulted in a striking
decrease in the levels of endogenous DNp63a (Figure 5a).
Within the time frame indicated, UV treatment did not
decrease the expression of DNp63a in control cells but
markedly did so in YAP-knockdown cells (Figure 5a).
Silencing of YAP had no effect on UV-induced JNK
activation itself, as evidenced by phospho-c-Jun immuno-
blotting (Figure 5a).
We wished to verify whether YAP-dependent stabilization
ofDNp63a isdue totheirdirect binding,aswasshownforYAP
and TAp73a.
12,13 Unstimulated HaCaT cells showed basal
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Cell Death and Diseasebinding of endogenous YAP and DNp63a, as detected by
co-IP with an anti-YAP antibody (Figure 5b). Strikingly, UV
treatment induced rapid and sustained increase in the binding
of endogenous YAP and DNp63a (Figure 5b), following the
kinetics of YAP phosphorylation by UV radiation in these cells
(Figure 3e).
It was shown that YAP stabilized p73 in part by displacing
the E3 ligase ITCH by competitive binding at the PPXY site on
p73.
12,13 ITCH was recently shown to bind and lead to
degradation of DNp63a, as well as TAp73a.
37,38 To further
understand the mechanism behind the YAP-mediated stabi-
lization of DNp63a, we assessed whether YAP stabilizes
DNp63a by interfering with ITCH binding; HaCaT cells were
transfected with either control or siRNA targeting ITCH.
Consistent with our observations in Figure 5b, co-IP with anti-
p63a antibody reveals endogenous YAP-p63 binding in
control HaCaT cells. Signiﬁcantly, silencing endogenous
ITCH in HaCaTs resulted in greater YAP-p63 binding as
shown by increased YAP co-immunoprecipitated with p63
(Figure 5c).
To ensure that these ﬁnding were not speciﬁc to HaCaT
cells, we assessed endogenous YAP stabilization of DNp63a
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Figure 4 YAPregulatesUV-inducedapoptosisin aJNK-dependentmanner.(a)HaCaTcontrolshRNA andYAP shRNAcellswereirradiatedwith UV-C(50J/m
2) for24h
orleft untreated. Apoptosiswas analyzedbyAnnexin-VandPIstainingby FACSasdetailedunderMaterialsandMethodsandinSupplementary FigureS3. (b)HaCaT stable
cell lines expressing the control shRNA or YAP-targeted shRNA where treated with anisomycin for 6h or irradiated with UV-C and harvested at the indicated time points.
Lysates were analyzed by Western blotting using the indicated antibodies. (c) BWT cells were treated with control or YAP-targeted siRNA and subsequently irradiated with
UV-C (30J/m
2) for 24h or left untreated.Apoptosis was analyzed as in panel a. Total includes early and late apoptosis.(d) BWT cells were treated with control or YAP siRNA
andirradiated as in panelc, andharvested at 2 and 6h. Lysateswere analyzedby Western blotting usingthe indicatedantibodies.(e) Flag-EV,or mut2DYAP was expressed
in BWT cells. Cells were irradiated with 30J/m
2 of UV-C or left untreated and analyzed for apoptosis as in panel c. The error bars indicate the standard deviation of three
independent experiments
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Cell Death and Diseasein the H357 head-and-neck squamous cell carcinoma line, as
DNp63a has been shown to be crucial for survival in this
cancer.
36 As shown in Figure 5d, silencing of endogenous
YAPin thesecellsleadstodecrease in DNp63aprotein levels.
Similar to HaCaT cells, DNp63a degradation resulting from
YAP loss is exacerbated by UV irradiation in this head-and-
neck cancer line (Figure 5d). Furthermore, we showed that
silencing of YAP in H357 cells not only results in decreased
DNp63a but also greater binding of endogenous DNp63a
and ITCH as determined by markedly increased ITCH
co-immunoprecipitated with p63 in YAP-depleted cells
(Figure 5e). Together, these results show that YAP-mediated
stabilization of DNp63a occurs through competitive binding
with the ITCH E3 ligase.
To further validate that YAP binding and stabilization of
DNp63a are mediated by the JNK phospho-sites on YAP,
we coexpressed DNp63a and either an empty control vector,
wild-type YAP, mut2AYAP or mut2DYAP in U2OS cells.
Complimentary to the effect of decreasing protein expression
of endogenous DNp63a by silencing YAP (Figure 5a),
ectopic expression of YAP stabilized coexpressed DNp63a
(Figure5f).Thiseffectwasenhancedwithcoexpressionofthe
phosphomimetic mut2DYAP but not with mut2AYAP
(Figure 5f). Furthermore, increased stabilization of DNp63a
by mut2DYAP correlated with increased binding of mut2-
DYAP to DNp63a, as compared with wild-type YAP
(Figure 5f), mimicking the effect of UV stimulation
(Figure 5b). Together, these results indicate that YAP
stabilization of DNp63a is regulated by their direct binding
and that it is induced by JNK phosphorylation.
Expression of DNp63a determines role of YAP in UV-
induced apoptosis. Western blot analysis showed that
DNp63a expression is high in HaCaT, where YAP silencing
promoted UV-induced apoptosis, and low in BWT where YAP
promoted UV-induced apoptosis (Figure 6a). Furthermore,
blotting with both pan-p63 and p63a-speciﬁc antibodies
and MW comparison showed that DNp63a is by far the
most prevalent p63 isoform expressed in both cell lines
(Figure 6a). To verify whether there is a causal link bet-
ween expression of DNp63a and whether YAP expression
promotes or protects from UV-induced apoptosis, we
manipulated the expression of DNp63a in these cells and
subjected them to UV irradiation. As expected, silencing
endogenous DNp63a expression in HaCaTs exacerbated
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Cell Death and DiseaseUV-induced cell death (Figure 6b), while ectopically
expressing DNp63a in BWT (Figure 6c) resulted in
decrease in apoptosis upon UV treatment.
Discussion
Our results show that YAP is a direct substrate for JNK
phosphorylation in a number of cell lines, both tumor-derived
(U20S, MCF-7, BWT) and immortalized (293, HaCaT)
(Figure 3a). We further show that JNK is stimulated to
phosphorylateYAPuponUVirradiation(Figure3e),oneofthe
most potent stress activators of the JNK pathway.
23,24,31
The studies that show YAP to promote apoptosis most
often used chemotherapeutics, such as cisplatin, to induce cell
death in tumor-derived cell lines.
7–9,11–13 Consistent with this
role, YAP has recently been shown to function as a tumor
suppressor in certain breast cancers.
39 However, YAP has
been shown to be a pro-growth signal in development, most
convincingly in ﬂy development,
14,15,18,19 and has also been
implicated as an oncogene in a mouse model of liver cancer.
40
It has been hypothesized that the apparent contradiction in the
function of YAP can be explained by YAP binding and
subsequently either activating or inactivating different tran-
scription factors, such as TAp73 to signal apoptosis and TEAD
to signal growth, as determined by context DNA damage in
adult tissue versus tissue growth in development.
10,17
In contrast to what has been reported for other DNA-
damaging signals, we show that YAP silencing enhances
UV-induced apoptosis in HaCaT cells (Figure 4a and b),
implicating a protective role for YAP in keratinocytes.
However, we found that YAP promotes UV-induced cell death
in BWT skin squamous cell carcinomas, further showing that
isdependentonJNKphosphorylation(Figure4c–e).Weshow
the mechanism behind this dual role of YAP in UV-induced
apoptosis to be the ability of YAP to stabilize the pro-
proliferative p53-family member, DNp63a, by direct binding,
similar to what has been shown previously with the proapop-
totic TAp73a.
12,13 Moreover, we show the binding and
stabilization of these key signaling proteins to be JNK-
dependent (Figure 5). Therefore, our studies indicate that
evaluation of the expression of the different p63/p73 isoforms,
which can signal opposing cell biologies,
41,42 is crucial in
determining the function of YAP, in different cell types, even
subject to the same stress stimuli.
Work on both DNA damage and tissue growth shows that
phosphorylation is a crucial regulatory process for YAP’s
function. Although we identiﬁed and characterized JNK as a
YAP kinase and a crucial regulator of its function, our initial
in vitro screen also suggests that there are other kinases,
besides those already published, that may directly phospho-
rylate YAP (Figure 1 and Supplementary Table 1). Forth-
coming studies will determine whether ERK2 and PKCa,
which both exhibited moderate in vitro kinase activity toward
YAP (Figure 1 and Supplementary Table 1), are physiologi-
cally relevant YAP kinases and whether their activity also
mediatesYAP’s regulationofapoptosisor growth.However, it
is likely that to fully appreciate YAP’s function in a particular
context, an integrative approach to phosphorylation, as well
as the other post-translational modiﬁcations reported for
YAP,
10,43 will be required.
Materials and Methods
YAP Kinase screen. See Supplementary Methods for details on YAP kinase
screens.
Cellculture,transfectionsandtreatments. U2OSandHaCaTcelllines
were grown in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum, L-glutamine and penicillin/streptomycin. The BWT human skin
squamous cell carcinoma line (a gift from Dr Karin Purdie (ICMS, Barts and The
London School of Medicine, Queen Mary University of London, London, UK)) was
grown in Dulbecco’s modiﬁed Eagle’s medium and F12 3:1 supplemented with
10% fetal bovine serum, adenine, hydrocortisone, insulin, epidermal growth factor,
cholera toxin, transferrin, liothyronine and penicillin/streptomycin. H357 head-and-
neck cancer cells were grown in Dulbecco’s modiﬁed Eagle’s medium supplemented
as BWT medium but excluding transferrin or liothyronine. Transfections of cDNA and
shRNA constructs were performed using Effectene (Qiagen, Crawley, West Sussex,
UK), according to the manufacturer’s instructions, either in six-well plates or 10-cm
dishes using 0.4 or 2mg of DNA, respectively. Cells were harvested 24 or 48h
after transfection. Interferin (Polyplus Transfection, New York, NY, USA) was used
for transfecting siRNA at a ﬁnal concentration of 10–25nM, according to the
manufacturer’s instructions, and cells were harvested 48h later. Anisomycin (Sigma,
Gillingham, Dorset, UK) was used at a ﬁnal concentration of 10mg/ml for 30–60min
before harvesting. The SP600125 and SB203580 inhibitors (Calbiochem, Merck
Chemicals Ltd., Nottingham, UK) were used for 3h before 15-min anisomycin
treatment at a concentration of 20 and 10mM, respectively. For UV-C treatments, cells
werewashedinPBSandirradiatedwith50J/m
2 (HaCaT) and 30J/m
2(BWT) of UV-C
and then incubated with normal media for the indicated time periods.
Plasmids and siRNAs. Flag–YAP was cloned from GFP-YAP as described
elsewhere,
7 into pCMV-Tag2B purchased from Stratagene (Agilent Technologies
UK Ltd., Stockport, UK). pcDNAHA-DNp63a was a gift from Dr Eleonora Candi
(Universita’ di Tor Vergata, Roma, Italy). Mutagenesis was performed using
the Quikchange Site-Directed Mutagenesis kit (Stratagene) according to the
manufacturer’s instructions. The primers used in the mutagenesis of YAP at JNK
phosphorylation sites to alanine and aspartic acid can be found in Supplementary
Methods. pRetroSuper was used to stably express an shRNA against YAP (YAP
shRNA); also used for YAP siRNA
7 and a non-targeting control (control shRNA).
44
TheJNK siRNA, which targets both JNK1and JNK2, and a non-targeting sequence
#2werebothpurchasedfromDharmacon(ThermoScientiﬁc,Northumberland,UK).
IPandWesternblotting. CellswereharvestedandlysedineitherNP40lysis
buffer or, for Flag IPs, in Flag lysis buffer (Sigma) containing protease and
phosphatase inhibitors. For Flag IPs, Flag beads (Sigma) were washed twice in
0.5% TBS and the lysates were incubated with the beads in 0.5–1ml of Flag lysis
buffer for 2h at 41C. After washing, proteins were eluted off the beads using
3 Flag peptide in a total volume of 50ml for 30min at 41C. For endogenous YAP
IPs, a monoclonal YAP1 antibody (MO1; Abnova Corporation, Heidelberg,
Germany) was used at 1.4mg/mg protein. For endogenous p63 IPs, p63a (H129;
Santa Cruz Biotechnology, Heidelberg, Germany) was used at 1mg/mg protein.
Protein-G–Sepharose beads (Sigma) were used according to the manufacturer’s
protocol. Proteins were analyzed by 8% SDS-PAGE and probed overnight with
primary antibodies, followed by incubation with HRP-coupled secondary antibodies
andchemiluminescencedetection(ECL).Thefollowingantibodieswereused:YAP,
p63a, (Santa Cruz Biotechnology); Flag, b-tubulin (Sigma); c-Jun, p-c-Jun, JNK,
PARPand cleaved PARP(Cell SignalingTechnology, NEB UK, Hitchin, UK); YAP1
(Abnova Corporation); and ITCH (BD Transduction Laboratories, Oxford, UK). The
YAP pT362 antibody was made by Kinasource (Dundee, UK) and was used in
conjunction with a dephospho-peptide.
In vitro kinase assay. Active JNK1a1 or JNK2a2 kinases (Upstate, Millipore
(U.K.) Limited, Watford, UK) were incubated with recombinant YAP protein along
with 100mM ATP (magnesium/ATP cocktail; Upstate) in a kinase buffer (10 ;
500mM Tris (pH 7.5), 100mM 2-ME) for 0 or 60min.
Massspectrometry. SamplesfrominvitrokinaseassaysorFlagIPswererun
onapre-cast4–12%NuPageBis–Trisgel (Invitrogen,Paisley,UK),whichwasthen
stained with Coomassie (GelCode Blue Stain Reagent; Pierce, Thermo Scientiﬁc,
Northumberland, UK). The band containing YAP was excised, digested with trypsin
andchymotrypsin,andtheresultantpeptidesweresubjectedtoLC-MS/MSanalysis
at the Protein Analysis Unit (WHRI, Barts and The London School of Medicine and
JNK phosphorylates Yes-associated protein (YAP)
V Tomlinson et al
8
Cell Death and DiseaseDentistry, Queen Mary University of London, London, UK) and the Taplin Mass
Spectrometry Facility (Harvard University). Spectra were analyzed for the
phosphorylation signature.
Annexin-V staining and ﬂow cytometry. HaCaT control shRNA (control
shRNA) or a YAP-targeted shRNA (YAP shRNA) stables were treated with 50J/m
2
UV-C. BWT cells were transiently transfected with the constructs and siRNAs
indicated, and irradiated 24h later with UV at 30J/m
2. Twenty-four hours after UV
irradiation, media and PBS wash as well as trypsinized cells were pelleted and
washed in PBS before a 15-min incubation with Annexin-V Alexa-488 and PI
according to the manufacturer’s instructions (Molecular Probes, Invitrogen). Flow
cytometry was performed using a FACSCalibur instrument (Becton Dickinson, BD
Biosciences, Oxford, UK) following the manufacturer’s instructions.
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